Moderna's Covid-19 Vaccine Is More Than 94% Effective, Preliminary Data Shows

Bulgaria Moderna's COVID-19 Vaccine Is 94.5 Percent Effective

Moderna released early results from a clinical trial with more than 30,000 participants, after United States pharmaceutical company Pfizer and its German partner BioNTech last week said their vaccine was 90% effective.

Moderna Inc. (NASDAQ:MRNA) announced its COVID-19 vaccine candidate is effective in preventing the disease 94.5% of the times.

The Moderna vaccine, which was co-developed by the US National Institutes of Health, is given in two doses 28 days apart, and the preliminary results are based on 95 volunteers of the 30,000 who fell ill with COVID-19.

Moderna expects to manufacture about 20 million doses of the vaccine this year.

Moderna's vaccine "enables a much more distributed model for us to get the vaccine out there, for example, in very rural areas and to be able to make that distribution process happen as conveniently as possible for those Americans that need vaccine", Hepburn said during a press call.

In an interview on BBC One's Andrew Marr Show, Prof Sahin said he expected further analysis to show the vaccine would reduce transmission between people and stop symptoms developing in someone who has had the vaccine.

Moderna is working with the U.S. Centers for Disease Control and Prevention (CDC), Operation Warp Speed and McKesson (NYSE: MCK), a COVID-19 vaccine distributor contracted by the U.S. government, as well as global stakeholders to be prepared for distribution of mRNA-1273, in the event that it receives an EUA and similar global authorizations.

More than 54 million cases of COVID-19 have been confirmed around the world, with the death toll topping one million, according to a tally by Johns Hopkins University.

Another bright spot: All 11 "severe cases" occurred in the placebo group and none in the mRNA-1273 vaccinated group.

Side effects included fatigue and muscle aches, but they were generally short-lived, the company said.

Crucially, Moderna also announced that its vaccine can remain stable at standard refrigerator temperatures of 2 degrees Celsius to 8 degrees Celsius for 30 days.

At lower temperatures of -20 degrees C (-4 degrees F), the Moderna vaccine remains stable for up to six months, the company reported.

The third phase of Moderna's trial on a coronavirus vaccine candidate involved some 30,000 participants, half of which took a placebo while the other half received the actual vaccine under development.

A Pfizer vaccine breakthrough a week ago came with a challenging cold chain component for storage and transportation.



Latest news

US disease experts recommend Americans don't travel for Thanksgiving
Thanksgiving and Christmas are typically the busiest times of year for domestic travel as Americans gather with friends and family around the country.

SpaceX Dragon Capsule Resilience Ferries Four Radio Amateurs to the ISS
Yoda was seen bobbing freely when the Crew Dragon separated from its Falcon 9 rocket en route to the space station. When SpaceX's Falcon 9 took off on Sunday night, the spaceflight company did something that it is getting good at.

Brexit talks suspended after negotiator tested positive for coronavirus
Prime Minister Boris Johnson was hospitalized in April and is now back in coronavirus quarantine until next Thursday. Mr Barnier added their teams would continue discussions in "full respect" of safety guidelines.

Los Angeles county imposes new Covid rules and readies for mandatory curfew
The number of patrons at outdoor restaurants, breweries and wineries will be limited to 50% max outdoor capacity. County, and it is certain that many more have been infected; The County has experienced a total of 7,363 deaths.

Priti Patel: Summary of official report into bullying claims
The report noted Ms Patel was "unaware" of the impact of her behaviour because no feedback was given to her at the time . Publication of the investigation's findings has been delayed for months by Prime Minister Boris Johnson's office.

Other news